Lambert-Eaton Myasthenic Syndrome Clinical Trial
Official title:
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).
Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if
they are medically stable. They may receive 3,4 diaminopyridine in addition to other
treatments and standard of care investigations for LEMS under supervision of the primary
investigator. Safety laboratory studies and EKGs will be obtained.
The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety
Monitoring Board.
The investigator has a hold on enrolling new subjects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| No longer available |
NCT01373333 -
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
|
N/A | |
| Completed |
NCT02970162 -
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
|
Phase 3 | |
| Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
| Recruiting |
NCT06441825 -
Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
|
||
| Completed |
NCT01511978 -
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
|
Phase 2 | |
| Completed |
NCT00004832 -
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
|
N/A | |
| No longer available |
NCT02189720 -
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
|
||
| Approved for marketing |
NCT00872950 -
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
|